AGIOS PHARMACEUTICALS, INC.
No enriched coverage for $AGIO in the last 7 days.
No SEC Form 4 filings for $AGIO in the last 30 days.
See all $AGIO insider activity →Cantor Fitzgerald reiterated an Overweight rating on Agios Pharma (AGIO). The FDA granted mitapivat’s supplemental NDA priority review and said no advisory committee is needed. Cantor estimates the thalassemia opportunity at about $500 million U.S. and $800 million worldwide, supporting an EV near $1 billion. Agios reported Q2 revenue $44.74M vs $26.57M estimate.
Analysts issued new ratings for GE Healthcare Technologies (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO). Bank of America kept GEHC at Hold with a $74 target; consensus is Moderate Buy at $79.07. Truist reiterated Buy on VRTX with consensus Strong Buy at $562.19. Truist reiterated Buy on AGIO; consensus Moderate Buy targets $41.33.
Gheuens Sarah (Chief Medical Officer) sold 30,000 shares of AGIOS PHARMACEUTICALS, INC. (AGIO) at $30.48 ($0.91M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
Recent AGIO coverage spans earnings, financial news and market movers.
Analyst reiteration is supported by a fresh FDA process update (priority review) and a quantified commercial opportunity thesis for mitapivat.
AGIO’s setup is more bullish than the consensus label suggests, with Buy reiterations and a large implied upside to average PT.
This is a routine insider sale under a 10b5-1 plan, so it is more a sentiment signal than a fundamental catalyst.
The FDA Priority Review and ongoing commercial traction for AQVESME are near-term catalysts, while pipeline updates and a halted program add offsetting risk.
The article frames a higher-than-consensus likelihood of an EPS beat for AGIO, setting up a near-term catalyst into the Q2 print.
alphai scores every news story that mentions AGIO with an AI model for sentiment and relevance, and aggregates insider trades from AGIOS PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cantor Fitzgerald reiterated an Overweight rating on Agios Pharma (AGIO). The FDA granted mitapivat’s supplemental NDA priority review and said no advisory committee is needed. Cantor estimates the thalassemia opportunity at about $500 million U.S. and $800 million worldwide, supporting an EV near $1 billion. Agios reported Q2 revenue $44.74M vs $26.57M estimate.
3 min readAnalysts issued new ratings for GE Healthcare Technologies (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO). Bank of America kept GEHC at Hold with a $74 target; consensus is Moderate Buy at $79.07. Truist reiterated Buy on VRTX with consensus Strong Buy at $562.19. Truist reiterated Buy on AGIO; consensus Moderate Buy targets $41.33.
2 min readGheuens Sarah (Chief Medical Officer) sold 30,000 shares of AGIOS PHARMACEUTICALS, INC. (AGIO) at $30.48 ($0.91M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
2 min readAGIOS PHARMACEUTICALS, INC. (AGIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Agios Reports Second Quarter 2026 Financial Results and Provides Business Update • Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025 • Strong U.S. commercial
6 min readZacks Investment Research says Agios Pharmaceuticals (AGIO) is expected to report Q2 results on July 30. Consensus calls for a quarterly loss of $1.86 per share, up 3.6% YoY, and revenue of $22.68 million, up 82.2%. Zacks reports an Earnings ESP of +12.67% and a Zacks Rank of #3, implying a likely EPS beat.
5 min readAgios Pharmaceuticals (AGIO) is scheduled to report Q2 2026 results on July 30 before market open, with earnings released at 6:30 AM ET. The consensus estimate cited for Q2 2026 is revenue of $26.07 million and EPS of -$1.66.
1 min readStocks rose as chipmakers and AI-infrastructure shares gained. The iShares Semiconductor ETF (SOXX) was up over 4%, with Teradyne (TER), Western Digital (WDC), Micron (MU), and Applied Materials (AMAT) among the biggest gainers. Rates moved with 10-year yields around 4.62% amid oil-led inflation expectations. Several companies reported earnings, including 3M, Hasbro, and General Motors.
6 min readStocks rose as chipmakers and AI-infrastructure shares rebounded. The iShares Semiconductor ETF (SOXX) gained over 3%, while Sandisk (SNDK), Micron (MU), Western Digital (WDC), and others rose. Bitcoin hit a 1-month high, lifting Coinbase (COIN) and Circle (CRCL). Hasbro (HAS) reported Q2 net revenue $1.14B and raised guidance; 3M (MMM) beat EPS and lifted outlook.
7 min readAgios Pharmaceuticals said it will discontinue development of its sickle cell disease treatment tebapivat after a mid-stage trial showed limited differentiation despite improvements in hemoglobin and hemolysis across doses. Shares fell about 4%. Agios said it will focus on mitapivat, with an FDA target action date of Nov. 1 for sickle cell.
6 min readAgios Pharmaceuticals (NASDAQ:AGIO) reported Phase 2 top-line results for tebapivat in sickle cell disease. The 12-week study (59 patients) showed hemoglobin and hemolysis improvements across doses, with 43.8% to 47.1% meeting a primary hemoglobin response versus 33.3% on placebo. Agios said it will stop development because results did not provide sufficient clinical differentiation. AGIO shares were down 7.11% to $37.21.
3 min read
